Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells.

Levy E, Ben Djoudi Ouadda A, Spahis S, Sane AT, Garofalo C, Grenier É, Emonnot L, Yara S, Couture P, Beaulieu JF, Ménard D, Seidah NG, Elchebly M.

Atherosclerosis. 2013 Apr;227(2):297-306. doi: 10.1016/j.atherosclerosis.2013.01.023. Epub 2013 Feb 4.

PMID:
23422832
2.

Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells.

Leblond F, Seidah NG, Précourt LP, Delvin E, Dominguez M, Levy E.

Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G805-15. doi: 10.1152/ajpgi.90424.2008. Epub 2009 Jan 29.

PMID:
19179626
3.

Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.

Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, Fazio S.

Circulation. 2014 Jul 29;130(5):431-41. doi: 10.1161/CIRCULATIONAHA.113.006720. Epub 2014 May 23. Erratum in: Circulation. 2015 May 5;131(18):e429.

4.

Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.

Duan Y, Chen Y, Hu W, Li X, Yang X, Zhou X, Yin Z, Kong D, Yao Z, Hajjar DP, Liu L, Liu Q, Han J.

J Biol Chem. 2012 Jul 6;287(28):23667-77. doi: 10.1074/jbc.M112.350181. Epub 2012 May 16.

5.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).

Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG.

PLoS One. 2013 May 13;8(5):e64145. doi: 10.1371/journal.pone.0064145. Print 2013.

6.

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.

Ferri N, Tibolla G, Pirillo A, Cipollone F, Mezzetti A, Pacia S, Corsini A, Catapano AL.

Atherosclerosis. 2012 Feb;220(2):381-6. doi: 10.1016/j.atherosclerosis.2011.11.026. Epub 2011 Nov 25.

PMID:
22176652
7.

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.

Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah NG.

J Biol Chem. 2008 Jan 25;283(4):2363-72. Epub 2007 Nov 26.

8.

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.

Urban D, Pöss J, Böhm M, Laufs U.

J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21. Review.

9.

MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression.

Yan H, Ma YL, Gui YZ, Wang SM, Wang XB, Gao F, Wang YP.

Acta Pharmacol Sin. 2014 Aug;35(8):994-1004. doi: 10.1038/aps.2014.52. Epub 2014 Jul 21.

10.

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.

Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A.

Hepatology. 2008 Aug;48(2):646-54. doi: 10.1002/hep.22354.

PMID:
18666258
11.

Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor.

Sun H, Samarghandi A, Zhang N, Yao Z, Xiong M, Teng BB.

Arterioscler Thromb Vasc Biol. 2012 Jul;32(7):1585-95. doi: 10.1161/ATVBAHA.112.250043. Epub 2012 May 10.

12.

Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.

Butkinaree C, Canuel M, Essalmani R, Poirier S, Benjannet S, Asselin MC, Roubtsova A, Hamelin J, Marcinkiewicz J, Chamberland A, Guillemot J, Mayer G, Sisodia SS, Jacob Y, Prat A, Seidah NG.

J Biol Chem. 2015 Jul 24;290(30):18609-20. doi: 10.1074/jbc.M115.647180. Epub 2015 Jun 17.

13.

On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.

Tavori H, Rashid S, Fazio S.

Atherosclerosis. 2015 Feb;238(2):264-70. doi: 10.1016/j.atherosclerosis.2014.12.017. Epub 2014 Dec 17. Review.

14.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells.

Lan H, Pang L, Smith MM, Levitan D, Ding W, Liu L, Shan L, Shah VV, Laverty M, Arreaza G, Zhang Q, Murgolo NJ, Hernandez M, Greene JR, Gustafson EL, Bayne ML, Davis HR, Hedrick JA.

J Cell Physiol. 2010 Jul;224(1):273-81. doi: 10.1002/jcp.22130.

PMID:
20333646
15.

In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor.

Min DK, Lee HS, Lee N, Lee CJ, Song HJ, Yang GE, Yoon D, Park SW.

Yonsei Med J. 2015 Sep;56(5):1251-7. doi: 10.3349/ymj.2015.56.5.1251.

16.

Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.

Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, Fazio S.

Circulation. 2013 Jun 18;127(24):2403-13. doi: 10.1161/CIRCULATIONAHA.113.001592. Epub 2013 May 20.

17.

β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.

Starr AE, Lemieux V, Noad J, Moore JI, Dewpura T, Raymond A, Chrétien M, Figeys D, Mayne J.

FEBS J. 2015 Jul;282(14):2682-96. doi: 10.1111/febs.13309. Epub 2015 May 18.

18.

Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.

Le QT, Blanchet M, Seidah NG, Labonté P.

J Biol Chem. 2015 Sep 18;290(38):23385-400. doi: 10.1074/jbc.M115.642991. Epub 2015 Jul 20.

19.

Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1.

Le May C, Berger JM, Lespine A, Pillot B, Prieur X, Letessier E, Hussain MM, Collet X, Cariou B, Costet P.

Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1484-93. doi: 10.1161/ATVBAHA.112.300263. Epub 2013 Apr 4.

20.

Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.

Sun X, Essalmani R, Day R, Khatib AM, Seidah NG, Prat A.

Neoplasia. 2012 Dec;14(12):1122-31.

Supplemental Content

Support Center